Korea To Reform Reimbursement Management To Cut Expenditure

To trim the healthcare financial burden and boost the country’s national health insurance coverage as planned, South Korea will introduce a drug re-evaluation system to adjust prices of both novel and generic drugs, drawing a negative response from the pharma industry.

Gangnam
Korea To Reallocate Resources Through Drug Re-evaluation • Source: Shutterstock

South Korea plans to conduct a re-evaluation of reimbursed drugs with a view to cutting their prices or delisting them from the national health insurance tariff if they fail to meet certain conditions, and also to lower prices of generics through regular comparisons with overseas prices.

Both moves are being mulled in an attempt to cut rising expenditure under the universal care system.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from South Korea

Korea Revamps Drug Review Processes, Cuts Approval Timelines

 
• By 

Under the new drug approval innovation measures, Korea will cut the review and approval period of new drugs to 295 days from 420 days and increase the number of expert reviewers to enhance review capabilities.

Korea’s Medical Vacuum Grows As Doctors Threaten Indefinite Walkout

 
• By 

Long-running protests by South Korean doctors against government reforms, including raising medical school admissions, continue to intensify with a one-day rally by community doctors and the threat of an indefinite walkout later this month. The pharma industry is also feeling the impact on clinical trials and sales. 

Korea’s Clinical Trial Approvals Up 10%, But Still Below Pandemic Peak

 
• By 

South Korea’s clinical trial approvals rebounded in 2023, but remained lower than the peak levels in 2020-21 amid then robust R&D activity related to COVID-19. Last year's tally showed a mix of single-country and multinational trials and reflected the ongoing dominance of oncology in industry pipelines.

Major Boost For WHO-Listed Authority Scheme As US & EU Regulators Designated

 

The US Food and Drug Administration and the European medicines regulatory network, which includes the European Commission, the European Medicines Agency and 30 national agencies, are now WHO-Listed Authorities under a framework launched in 2022.

More from Asia

Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

 
• By 

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By 

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By 

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.